Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New FDA Pilot Program To Finger ‘Critical-To-Quality’ Points; First Up: Implantables With Batteries

This article was originally published in The Silver Sheet

Executive Summary

A “critical-to-quality” pilot program will launch early next year to help hone FDA investigators’ attention on manufacturing processes that are essential to the quality of implantable devices that include batteries. The agency, along with manufacturers and other stakeholders, will develop so-called “CTQs” that investigators will use to supplement FDA’s traditional QSIT inspectional approach. If the pilot goes well, FDA will likely develop a similar CTQ model for inspections of manufacturers that make devices other than implantables with batteries. Next for potential CTQS: cardiovascular products, IVDs, and general hospital and surgical devices?

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036727

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel